Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · May 02, 2023

Overall Survival and Safety Outcomes of Olaparib vs Chemotherapy Treatment of Physician's Choice in Patients With a Germline BRCA Mutation and HER2− MBC

European Journal of Cancer


Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
OlympiAD extended follow-up for overall survival and safety: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
Eur. J. Cancer 2023 May 01;184(xx)39-47, ME Robson, SA Im, E Senkus, B Xu, SM Domchek, N Masuda, S Delaloge, N Tung, A Armstrong, M Dymond, A Fielding, A Allen, P Conte

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading